Anti-phospholipid antibodies in COVID-19 are different from those detectable

in the anti-phospholipid syndrome. 2

- Maria Orietta Borghi^{*,†}, Asmaa Beltagy^{*,‡}, Emirena Garrafa^{§,¶}, Daniele Curreli^{*}, Germana Cecchini^{**}, Caterina Bodio^{*}, Claudia Grossi^{*}, Simonetta Blengino^{††}, Angela Tincani^{‡‡}, Franco 3
- 4
- Franceschini^{‡‡}, Laura Andreoli^{‡‡}, Maria Grazia Lazzaroni^{‡‡}, Silvia Piantoni^{‡‡}, Stefania Masneri^{‡‡}, 5
- Francesca Crisafulli^{‡‡}, Duilio Brugnoni[¶], Maria Lorenza Muiesan^{§§}, Massimo Salvetti^{§§}, Gianfranco 6
- Parati^{††}, Erminio Torresani^{**}, Michael Mahler[¶], Francesca Heilbron^{††}, Francesca Pregnolato^{*}, Martino Pengo^{††}, Francesco Tedesco^{*}, Nicola Pozzi^{***,#}, Pier Luigi Meroni^{*,#} 7
- 8
- *Istituto Auxologico Italiano, IRCCS, Immunorheumatology Research Laboratory, Milan, Italy. 10
- [†]Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 11
- 12 [‡]Rheumatology and Clinical Immunology Department, Faculty of Medicine, Alexandria University,
- 13 Alexandria, Egypt.

1

9

26

36

39

41

- §Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 14
- Department of Laboratory Diagnostics, ASST Spedali Civili, Brescia, Italy. 15
- **Istituto Auxologico Italiano, IRCCS, Department of Chemical Chemistry, Milan, Italy. 16
- 17 ^{††}Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic
- Sciences, San Luca Hospital, Milan, Italy. 18
- 19 ^{‡‡}Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental
- 20 Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy.
- 21 §§UOC 2° Medicina, Department of Clinical and Experimental Sciences, ASST Spedali Civili and
- 22 University of Brescia, Brescia, Italy.
- 23 ¶Inova Diagnostics, Inc., San Diego, CA, USA.
- ***Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, 24
- 25 St. Louis, MO, USA.

27 Correspondence

- *Corresponding author: 28
- 29 Pier Luigi Meroni, Immunorheumatology Research Laboratory, Istituto Auxologico Italiano, Via
- 30 Zucchi 18, 20095 Cusano Milanino (MI), Italy
- 31 Phone number: +39-02-619113033; e-mail: pierluigi.meroni@unimi.it
- 32 *Co-corresponding Author:
- 33 Nicola Pozzi, Department of Biochemistry and Molecular Biology, Saint Louis University School
- 34 of Medicine, 1100 South Grand Blvd., St. Louis, MO 63104, USA
- 35 Phone number: +1-314-9779241; e-mail: nicola.pozzi@health.slu.edu
- 37 **Key words** Anti-phospholipid antibodies, β_2 glycoprotein I, prothrombin, autoimmunity, COVID-
- 38 19, thrombosis.
- 40 Running Head: aPL antibodies and COVID-19
- 42 Total words: 1709
- 43 Figures N.3
- 44 Tables: N.2

Abstract

- **Background.** Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with antiphospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β₂GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β₂GPI antibodies was not reported.
- Objective. To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β₂GPI antibodies.
- Methods. ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events.
- Results. Anti- β_2 GPI IgG/IgA/IgM were the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM were detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β_2 GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti- β_2 GPI nor with thrombosis.
- Conclusions. aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β_2 GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.

1. Introduction

74

- 75 Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable 76 state and often develop thrombosis in veins, arteries and in the microcirculation [1,2]. Recent 77 analysis showed several coagulation abnormalities in these patients, including prominent elevation 78 of fibrin/fibrinogen degradation products (i.e., D-dimer) and a prolonged activated partial-79 thromboplastin time (aPTT). While high levels of D-dimer are consistent with sustained activation 80 of the clotting and fibrinolytic cascades, the combination of prolonged aPTT and both arterial and 81 venous thrombosis was, however, surprising, and it is reminiscent of a clinical scenario known as 82 antiphospholipid syndrome (APS) [3].
- Looking at the causes for aPTT prolongation, recent studies have shown that lupus anticoagulant (LA) can be detected in a significant percentage of COVID-19 samples [4-6]. Since LA is often caused by aPL, these findings support the idea that aPL may play a role in COVID-19[7]. However, it is important to point out that LA is a very sensitive assay and its outcome can be influenced by several factors, most notably heparin administration [8] and a profound inflammatory state characterized by high levels of C reactive protein (CRP) [9,10]. Both of them are present in COVID-19 patients [11].
- 90 Another method to detect aPL that is in principle insensitive to anticoagulation and other 91 confounding agents relies on the detection and quantification of autoantibodies using solid phase 92 assays[3]. Using this method, the presence of aPL was recently reported in a handful of case reports 93 and small cohorts of patients [4,6,7,12,13]. While encouraging, this data is limited and its 94 interpretation remains controversial, with some investigators proposing an important role of aPL in 95 COVID-19 patients[7] while others suggesting a very poor correlation between aPL and thrombotic 96 events [14]. There is no information on the antigen specificity of COVID-19 aPL in comparison 97 with APS antibodies. Such information and a larger study, possibly multicenter, may be 98 instrumental to clarify the real clinical value of these autoantibodies.

2. Materials and methods

2.1 Patients

99 100

101 102

103

104

105

106

107

108

109

110

111 112

118

A total of 122 patients were enrolled from two COVID-19 referral centers in Lombardia. All patients tested positive to SARS-CoV-2, and classified as severe or critical COVID-19 [11]. Mean age was 68.5 (\pm SD 16.4) years; 77 were men and 45 women. No diagnosis of previous autoimmune diseases was made; six patients had a thrombotic event (three arterial and three venous) in the past clinical history. Eighty-seven patients suffering from APS were also tested for anti-cardiolipin (aCL) and anti- β_2 GPI IgG/IgM [15]. The study was approved by the Ethics Committees (Istituto Auxologico Italiano 3-04-2020 - Milan and ASST Spedali Civili NP4187 - Brescia).

2.2 Detection of aPL

- 113 Anti-cardiolipin and anti-β₂GPI IgG/IgA/IgM were detected by chemiluminescence immunoassay
- 114 (CIA; Quanta Flash, Inova, San Diego, CA, US) and a home-made ELISA as described [15,16].
- Anti- β_2 GPI domain 1 IgG (anti-D1) were detected by CIA[15,16], IgG anti-D4-5 by a home-made
- 116 ELISA, as described [15,16]. Anti-phosphatidylserine/prothrombin (aPS/PT) IgG/IgM were
- detected by a commercial ELISA as reported[17].

119 2.3 Statistical analysis

- Data were analyzed using R v3.4.0. Descriptive statistics was used to summarize data. Associations
- and differences between categorical or continuous variables were tested by Fisher's exact test and
- 122 non-parametric Mann-Whitney test, respectively. A p-value <0.05 was considered statistically
- significant.

3. Results

3.1 Patients

Table 1 reports the median with minimum and maximum values for different coagulation and inflammation parameters in 122 severe or critical COVID-19 patients. In particular, prolonged aPTT (>30 sec) was found in 57.6% while PT INR values were above the cut-off in 24.8% of the cases. Most of the patients (120/122) were on anticoagulation with low molecular weight heparin (70% on therapeutic and the remaining on prophylactic dosage). Despite anticoagulation, we observed sixteen thrombotic events (13.1%, 8 in veins and 8 in arteries). These statistics are in agreement with previous reports[2,18-23] and document a systemic inflammation and a coagulopathy in our patients.

3.2 Anti-cardiolipin and anti- β_2 GPI antibody testing.

In the APS field, testing for LA is not recommended when patients are on heparin, since the presence of heparin, even if neutralized, may lead to false positive results [8]. Likewise, high levels CRP, such as those found in our cohort of patients, have been shown to prolong aPTT independently from the presence of aPL[9,10]. On these bases, the presence of aPL was researched using solid phase assays, and not LA. First, we investigated the presence of aCL and anti- β_2 GPI, two APS classification criteria[3]. Testing was independently performed in Milan and Brescia, using harmonized methodologies[24]. The prevalence of COVID-19 patients positive for aCL and anti- β_2 GPI IgG/IgA/IgM detected by ELISA and CIA is summarized in Table 2. The ELISA raw data are shown in Fig. 1. We found IgG/IgM aCL in 5.7/6.6% of patients, whereas anti- β_2 GPI IgG/IgA/IgM were found in 15.6/6.6/9.0% of patients. Similar values were obtained for aCL antibodies using CIA (Table 1), whereas a slightly lower sensitivity was obtained for anti- β_2 GPI antibodies [25]. The positivity for aCL and anti- β_2 GPI antibodies was at medium/low titer in contrast with the medium/high titers found in the control group of primary APS (Figure 1). There is no association between aPL positivity and thrombotic events.

3.3 Epitope characterization of anti-β₂GPI antibodies

Fifty-eight sera were also tested with D1 and D4-5-coated plates in order to characterize their epitope specificity. Fig. 2B shows that three out of 58 samples reacted with D1, while in Fig. 2C, three samples tested positive for D4-5. None of the sera was positive for both domains and all displayed a weak reactivity with no association with thrombosis.

3.4 Anti-phosphatidylserine/prothrombin antibody testing

Prolonged aPTT (>30 sec) was found in 57.6% of the patients. Although aPS/PT are not included in the APS classification laboratory tests, they can be associated with a prolonged aPTT and with the presence of LA[17]. Consequently, we looked at the presence of aPS/PT antibodies in our cohort and we found fifteen out of 122 sera positive for aPS/PT (12.3%), mostly of the IgM isotype (12 out 15) and at a low titer (Fig. 3). There was no association between prolonged aPTT and the presence of aPS/PT antibodies nor with thrombotic events in our COVID-19 cohort.

4. Discussion

Taken together, our data shows a low prevalence of classification criteria aPL in COVID-19 patients. In this regard, our study confirms recent studies obtained with smaller cohorts of patients [4,14,23]. Importantly, our data also shows that aPL are slightly more reactive towards β_2 GPI-coated plates as compared to CL-coated ones and that, regardless of the nature of aPL, there is no association between aPL positivity and thrombotic events (p=1).

A striking difference between the autoantibody profile in COVID-19 patients as compared to the one in APS concerned the titers of aPL. Medium/low aPL titers were consistently found in the

175 patients with COVID-19. By contrast, medium/high titers are usually found in APS patients (Fig. 176 1). This difference suggests that aPL found in COVID-19 may be different from aPL found in APS 177 and led us to further investigate the epitope specificity of anti- β_2 GPI antibodies. We focused on 178 autoantibodies directed against the N-terminal domain 1 (anti-D1) or the C-terminal domains 4-5 179 (anti-D4-5) of the molecule [16] (Fig. 2A). This is because anti-D1 antibodies are associated with an 180 increased risk of thrombosis and pregnancy complications in APS[15,16,26]. By contrast, anti D4-5 181 antibodies are associated neither with vascular nor obstetric APS manifestations[15.27]. 182 Furthermore, anti D4-5 antibodies are also reported at high levels in the so called asymptomatic 183 aPL carriers and are frequently found in non-APS (e.g. patients with leprosy, atopic dermatitis, 184 atherosclerosis and in children born to mothers with systemic autoimmune diseases) [27]. We found 185 that three out of 58 samples reacted with D1, and three samples tested positive for D4-5. None of 186 the sera was positive for both domains and all displayed a weak reactivity. Although the number of 187 the investigated sera is relatively small, this finding is quite different from the results found in APS 188 in which almost all the sera positive for the whole β_2 GPI molecule also reacted with domain D1 at 189 high titer[15,26]. Furthermore, at variance with APS patients, none of the anti-D1 positive patients 190 displayed thrombotic events[26].

191 Approximately fifty-seven per cent of COVID-19 patients has prolonged aPTT. Yet, only a small 192 proportion of COVID-19 patients carry aCL and anti-β₂GPI antibodies. This suggests that other 193 factors must be responsible for the prolonged aPTT phenomenon. Since aPS/PT can be associated 194 with a prolonged aPTT and with the presence of LA[17], we tested our cohort for aPS/PT 195 antibodies. We found a small percentage (12.3%) of positive sera, mostly of the IgM isotype (12 out 196 15) and at a low titer. Again there was no association between prolonged aPTT and the presence of 197 aPS/PT antibodies nor with thrombotic events in our COVID-19 cohort. This indicates that aPS/PT 198 are not responsible for the prolongation of aPTT nor are predictors of adverse clinical outcomes. 199 Furthermore, in contrast to what we would have expected in APS[28], we found no associations 200 between the presence of aPS/PT, aCL and anti- β_2 GPI antibodies. This data is in line with the 201 unusual epitope specificity of anti- β_2 GPI antibodies documented in Fig. 2, supporting the 202 hypothesis that aPL found in COVID-19 patients are different from aPL found in APS patients. 203 Whether COVID-19 aPL are similar to the ones found in other infectious diseases such as HCV, 204 HBV and HIV[29] remains to be determined.

205 In conclusion, while medium/high aPL titers with D1 specificity are associated with vascular events 206 in APS, low antibody titers with reactivity against β₂GPI epitope(s) different from D1 or D4,5 can 207 be found in COVID-19. This may explain the lack of association with thrombotic events in 208 COVID-19. In addition, our data do not support the hypothesis that aPL can be the main cause of 209 prolonged aPTT in these patients. Although low titer aPL are not predictive of vascular events in 210 the APS, it is important to keep in mind that COVID-19 patients suffer from an acute form of 211 systemic inflammation with complement activation[30], which may be responsible for endothelial 212 perturbation. In this context, since β₂GPI can accumulate on the activated endothelium at high 213 density, even low titers of aPL may become pathogenic thus potentiating or even triggering 214 thrombus formation, especially when anticoagulation is suspended. A comparable condition in 215 which low titers of aPL can cause substantial damage is seen in obstetric APS, where high levels of 216 β₂GPI can be found in the placenta[31]. Hence, while transitory aPL are likely to be clinically 217 irrelevant in COVID-19 patients as in other infections[29], detection of aPL may be useful for 218 identifying patients potentially at risk of thrombosis after the hospital discharge. Accordingly, an 219 anticoagulant prophylaxis could be justified before a confirmatory assay[3]. 220

5. Authorship

221

M.O. Borghi, M. Pengo, A. Tincani, F. Franceschini, F. Tedesco, N. Pozzi, P.L. Meroni designed the study; S. Blengino, G. Parati, F. Heilbron, M. Pengo, M.G. Lazzaroni, M.L. Muiesan, M.

- 224 Salvetti collected clinical samples; E. Garrafa, D. Curreli, G. Cecchini, C. Bodio, C. Grossi, S.
- Piantoni, S. Masneri, F. Crisafulli, D. Brugnoni, E. Torresani, M. Mahler, L. Andreoli, performed
- research; M.O. Borghi, A. Beltagy, F. Pregnolato, F. Tedesco, N. Pozzi, P.L. Meroni analyzed data;
- M.O. Borghi, F. Tedesco, N. Pozzi, P.L. Meroni wrote the manuscript. All authors reviewed and approved the manuscript.

6. Acknowledgment

The study was in part supported by IRCCS Istituto Auxologico Italiano - Ricerca Corrente 2019 (PL Meroni), a grant from the Italian Ministry of Foreign Affairs and International Cooperation (MAECI) for foreign citizens and Italian citizens living abroad (A. Beltagy) and a National Institutes of Health Research Grant HL150146 (N. Pozzi). The Authors would like to thank: Drs. N. Carabellese and G. Martini (Department of Laboratory Diagnostics; ASST Spedali Civili, Brescia, Italy) for their valuable collaboration; all the physicians of the COVID-19 Units of the IRCCS Istituto Auxologico Italiano (Milan) and the ASST Spedali Civili (Brescia).

7. Conflict of interests

M. Mahler is an employee at Inova Diagnostics, Inc. All the other authors declared no conflict of interest.

8. References

275276277

278

- 279 1. Carsana L., Sonzogni A., Nasr A., Rossi R.S., Pellegrinelli A., Zerbi P. *et al.* Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. medRxiv 2020:2020.04.19.20054262. doi:10.1016/S1473-3099(20)30434-5[Epub ahead of print].
- 282 2. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; 18: 844-7. doi:10.1111/jth.14768
- Garcia D., Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. *N Engl J Med* 2018; 378: 2010-21.doi:10.1056/NEJMra1705454
- 4. Harzallah I., Debliquis A., Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. *J Thromb Haemost* 2020; 10.1111/jth.14867. doi:10.1111/jth.14867
- Bowles L., Platton S., Yartey N., Dave M., Lee K., Hart D.P. *et al.* Lupus Anticoagulant and
 Abnormal Coagulation Tests in Patients with Covid-19. *N Engl J Med* 2020;
 NEJMc2013656. doi:10.1056/NEJMc2013656
- Pineton de Chambrun M., Frere C., Miyara M., Amoura Z., Martin-Toutain I. Mathian A. et
 al. High Frequency of Antiphospholipid Antibodies in Critically-ill COVID-19 Patients: a
 Link with Hypercoagulability? J Intern Med 2020; 10.1111/joim.13126.
 doi:10.1111/joim.13126
- Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W. *et al.* Coagulopathy and
 Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med* 2020; 382: e38.
 doi:10.1056/NEJMc2007575
- Martinuzzo M.E., Barrera L.H., D 'Adamo M.A., Otaso J.C., Gimenez M.I., Oyhamburu J. Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. *Int J Lab Hematol* 2014; 36: 144-50. doi:10.1111/ijlh.12138
- Schouwers S.M.E., Delanghe J.R., Devreese K.M.J. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: Does C-reactive protein interfere with LAC test results?
 Thromb Res 2010; 125: 102-4. doi:10.1016/j.thromres.2009.09.001
- 306 10. Ruinemans-Koerts J., Ahmed-Ousenkova Y.M., Kaasjager H.A.H., Hendriks-van Wijhe C., 307 Hovens M.M.C. When to screen for lupus anticoagulant? Influence of testing during acute 308 phase and consequences for clinical practise. *Lupus* 2015; 24: 1233-5. 309 doi:10.1177/0961203315583540
- Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. *et al.* Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; 130: 2620-9. doi:10.1172/JCI137244
- 313 12. Zuo Y., Estes S.K., Gandhi A.A., Yalavarthi S., Ali R.A., Shi H. *et al.* Prothrombotic antiphospholipid antibodies in COVID-19. *medRxiv* 2020: 2020.06.15.20131607.
 315 doi:10.1101/2020.06.15.20131607 [Epub ahead of print].
- Xiao M., Zhang Y., Zhang S., Qin X., Xia P., Cao W. *et al.* Brief Report: Anti-phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID-19). *Arthritis Rheumatol* 2020; 10.1002/art.41425. doi:10.1002/art.41425
- 319 14. Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J., Del Toro-Cervera J., Di Natale M. *et al.* Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. *Thromb Res* 2020; 192: 113-5.
- 322 doi:10.1016/j.thromres.2020.05.017

- Chighizola C.B., Pregnolato F., Andreoli L., Bodio C., Cesana L., Comerio C. *et al.* Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in antiphospholipid syndrome. *J Autoimmun* 2018; 90: 76-83. doi:10.1016/j.jaut.2018.02.002
- Durigutto P., Grossi C., Borghi M.O., Macor P., Pregnolato F., Raschi E. *et al.* New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. *Haematologica* 2019; 104: 819-26. doi:10.3324/haematol.2018.198119
- 329 17. Tincani A., Morozzi G., Afeltra A., Alessandri C., Allegri F., Bistoni O. et al.
- Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods.
- A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). *Clin Exp Rheumatol* 2007; 25: 268-74.
- Nahum J., Morichau-Beauchant T., Daviaud F., Echegut P., Fichet J., Maillet J.M. *et al.* Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID *JAMA Network Open* 2020; 3: e2010478-e. doi:10.1001/jamanetworkopen.2020.10478
- Zhang L., Feng X., Zhang D., Jiang C., Mei H., Wang J. *et al.* Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China:
 Prevalence, Risk Factors, and Outcome. *Circulation* 2020;
- doi:10.1161/CIRCULATIONAHA.120.046702 [Epub ahead of print].
- 340 20. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M. *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020; 191: 145-7. doi:10.1016/j.thromres.2020.04.013
- Lodigiani C., Iapichino G., Carenzo L., Cecconi M., Ferrazzi P., Sebastian T. *et al.* Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res* 2020; 191: 9-14. doi:10.1016/j.thromres.2020.04.024
- Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Müller M.C.A. *et al.* Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* 2020; 10.1111/jth.14888. doi:10.1111/jth.14888
- 349 23. Beyrouti R., Adams M.E., Benjamin L., Cohen H., Farmer S.F., Goh Y.Y. *et al.* 350 Characteristics of ischaemic stroke associated with COVID-19. *J Neurol Neurosurg* 351 *Psychiatry* 2020; jnnp-2020-323586. [Epub ahead of print]. doi:10.1136/jnnp-2020-323586
- Andreoli L, Rizzini S, Allegri F, Meroni P, Tincani A. Are the Current Attempts at
 Standardization of Antiphospholipid Antibodies Still Useful? Emerging Technologies Signal
 Shift in Direction. Semin Thromb Hemost 2008; 34: 356-60. doi:10.1055/s-0028-1085478
- Lakos G., Bentow C., Mahler M. A Clinical Approach for Defining the Threshold between Low and Medium Anti-Cardiolipin Antibody Levels for QUANTA Flash Assays. *Antibodies* (*Basel, Switzerland*). 2016; 5: 14. doi:10.3390/antib5020014
- Radin M., Cecchi I., Roccatello D., Meroni P.L., Sciascia S. Prevalence and Thrombotic
 Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review.
 Semin Thromb Hemost 2018; 44: 466-74. doi:10.1055/s-0037-1603936
- Andreoli L., Chighizola C.B., Nalli C., Gerosa M., Borghi M.O., Pregnolato F. *et al.* Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. *Arthritis Rheumatol* 2015; 67: 2196-204. doi:10.1002/art.39187
- Cattini M.G., Bison E., Pontara E., Cheng C., Denas G., Pengo V. Tetra positive thrombotic
 antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin
 antibodies to lupus anticoagulant activity. *J Thromb Haemost* 2020; 18: 1124-32.
 doi:10.1111/jth.14765
- 370 29. García-Carrasco M., Galarza-Maldonado C., Mendoza-Pinto C., Escarcega R.O., Cervera R.
 371 Infections and the Antiphospholipid Syndrome. *Clin Rev Allergy Immunol* 2009; 36: 104-8.
 372 doi:10.1007/s12016-008-8103-0

- 373 30. Cugno M., Meroni P.L., Gualtierotti R., Griffini S., Grovetti E., Torri A. *et al.* Complement activation in patients with COVID-19: A novel therapeutic target. *J Allergy Clin Immunol* 2020; S0091-6749(20)30650-3. doi:10.1016/j.jaci.2020.05.006
- 37. Pregnolato F., Gerosa M., Raimondo M.G., Comerio C., Bartoli F., Lonati P.A. *et al.*37. EUREKA algorithm predicts obstetric risk and response to treatment in women with
 37. different subsets of anti-phospholipid antibodies. *Rheumatolog y (Oxford)* 2020; keaa203.
 37. doi:10.1093/rheumatology/keaa203 [Epub ahead of print].
- 380 32. Ruben E.A., Planer W., Chinnaraj M., Chen Z., Zuo X., Pengo V. *et al.* The J-elongated conformation of beta2-glycoprotein I predominates in solution: Implications for our understanding of antiphospholipid syndrome. *J Biol Chem* 2020; jbc.RA120.013939. doi:10.1074/jbc.RA120.013939

9. Figure legends

Figure 1. Titers of aCL and a β_2 GPI antibodies detected by ELISA in COVID-19 patients (black, n=122) and comparison with APS patients (green, n=86).

Values are expressed as median levels [first and third quartile]. **Panel A:** aCL. From the left to the right: COVID-19 IgG: 15 [8 - 15]; APS IgG: 65 [22 - 103]; COVID-19 IgM: 6.2 [2.6 - 10.8]; and APS IgM: 4.0 [1 - 11]. **Panel B:** a β_2 GPI. From the left to the right: COVID-19 IgG: 0.06 [0.04 - 0.10]; APS IgG: 1.14 [0.52– 1.55]; COVID-19 IgM: 0.065 [0.02 – 0.142]; APS IgM: 0.23 [0.105 – 0.741]; and COVID-19 IgA: 0.04 [0.02 – 0.09]. Cutoff values are aCL IgG/IgM 20 phospholipid units (GPL/MPL); a β_2 GPI IgG/IgM/ IgA ELISA 0.13, 0.27 and 0.16 optical units (OD), respectively.

Figure 2. Epitope specificity of anti-β₂GPI antibodies in COVID-19 patients. Panel A.

Three-dimensional structure of β_2 GPI solved at 2.4 Å by X-ray crystallography (PDI ID: 6V06 [32]) displaying the positioning of the fragments used in this study. The N-terminal D1 is shown in red. The C-terminal D4-5 fragment is shown in blue. N-linked glycosylations are shown as magenta stick. Titers of anti-D1 (**panel B**) and anti-D4-5 antibodies (**panel C**) in 58 COVID-19 patients detected by chemiluminescence and ELISA, respectively. Values are expressed as median levels [first and third quartile]. Anti-D1(aD1): 3.6 [3.6 – 4.7]. Anti-D4-D5 (aD4-D5): 0.10 [0.068 – 0.199]. Cutoff values are >20 chemiluminescent units (CU) and >0.405 optical units (OD) for aD1 and aD4-D5, respectively.

Figure 3. Titers of aPS/PT antibodies detected by ELISA in COVID-19 patients.

Values are expressed as median levels [first and third quartile]. aPS/PT IgG:13.6 [8 to 15.2]; aPS/PT IgM:11.4 [8 to 16.5] IgM. Cut-off of the assays was 30 units/ml.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.17.20134114; this version posted July 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 1. Coagulation and inflammation parameters expressed as median with minimum and maximum in severe or critical COVID-19 patients.

	D-dimer	CRP	Ferritin	IL-6	White cells	Neuthrophils	Platelets	PT	aPTT	Fibrinogen
	μg/L	mg/dl	μg/L	ng/L	n/μl	n/μl	$n \times 10^3/\mu l$	ratio	sec	mg/dl
COVID-19	984.47	126.99	1024	25.1	8000	6600	350	1.196	30.13	521
	200 40224	0.1.470.2	<i>55</i> ,0002	2 406	2500 12000	1560 12510	60.900	0060	21.75.4	202 940
	200-40234	0.1-470.3	55-9002	3-496	2500-12900	1560-12510	60-800	0.9-6.9	21-75.4	202-840
Normal range	< 500	0.00-0.05	30-400	< 10	4300-10500	1800-8100	140-450	<u>< 1.2</u>	< 30 sec	200-400

Table 2. Prevalence of COVID-19 patients positive for aPL

	EL	ISA	C	CIA
	aCL	aβ ₂ GPI	aCL CIA	aβ ₂ GPI CIA
IgG	5.7 (7)*	15.6 (19)	9.8 (12)	5.0 (6)
IgM	6.6 (8)	9.0 (11)	6.6 (8)	5.0 (6)
IgA	nd	6.6 (8)	2.5 (3)	0.8 (1)

^{*}Values are expressed as percentage (n) of positive patients. aCL: anti-cardiolipin antibodies; a β_2 GPI: anti- β_2 glycoprotein I antibodies; ELISA: enzyme linked immunosorbent assay; CIA: chemiluminescence immunoassay; nd: not done.

Figure 1




Figure 2




Figure 3

